Characterization of Anti-GAD65-Associated Neurological Syndromes: Clinical Features and Antibody Titers
NeuroSci · 17.06.2024 · 5 (2) · 201-208
DOI: 10.3390/neurosci5020015 ↗Kurz gefasst
Fachartikel in der Zeitschrift NeuroSci, online erschienen am 17.06.2024. Verfasst von João Moura und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Hospital de Santo António, Centro Hospitalar Universitário do Porto, 4099-001 Porto, Portugalernestinasantos.neurologia@chpo…. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Anti-GAD65 antibodies are associated with several neurological phenotypes. Antibody titers are increasingly recognized as useful in diagnosis and prognosis.
Objective
To describe a Portuguese cohort of patients with anti-GAD65-associated neurological syndromes.
Methods
Retrospective analysis of all patients with positive anti-GAD65 antibodies and associated neurological syndromes followed in a tertiary referral center.
Results
Nineteen anti-GAD65 antibody-positive neurological patients were identified, 62.3% female, with a mean age of onset of 56.0 (SD = 13.3) years. Comorbid autoimmune disorders were present in seven patients. Six patients had limbic encephalitis (31.6%), four had epilepsy (21.1%), four had cerebellar ataxia (21.1%), and three had stiff-person syndrome (15.8%). Two patients presented with isolated cognitive dysfunction (executive and mnesic) in the absence of other neurological symptoms. The mean follow-up time was 24.0 (14.0–42.0) months, at the end of which the mean modified Rankin Scale (mRS) value was 2.0 (1.0–4.0). Screening for malignancies was negative in all patients. Serum quantitative analysis was carried out in 18 patients, 10 of whom showed titers above previously defined cut-off points (>10,000 IU/L for ELISA and >20 mmol/L for RIA). Quantitative CSF analysis was performed in nine patients, with four showing above-threshold titers. There was no association between anti-GAD65 levels and clinical phenotype or the final mRS values. High-dose intravenous methylprednisolone and oral prednisolone were the most common acute and chronic treatment regimens, respectively.
Conclusion
Anti-GAD65 antibodies are associated with varied neurological syndromes, and antibody titers alone should not be used to exclude a disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Hospital de Santo António, Centro Hospitalar Universitário do Porto, 4099-001 Porto, Portugalernestinasantos.neurologia@chporto.min-saude.pt (E.S.).
- Department of Neurophysiology, Hospital de Santo António, Centro Hospitalar Universitário do Porto, 4099-001 Porto, Portugal.
- Department of Immunology, Hospital de Santo António, Centro Hospitalar Universitário do Porto, 4099-001 Porto, Portugal.
- Unit of Multidisciplinary Research in Biomedicine (UMIB), Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, 4099-001 Porto, Portugal.
- Laboratory for Integrative and Translational Research in Population Health (ITR), 4099-001 Porto, Portugal.
ORCID-Profile: João Moura, Firmina Sambayeta, Ana Paula Sousa, Paula Carneiro, Raquel Samões
Zitieren
APA
Moura, J., Sambayeta, F., Sousa, A. P., Carneiro, P., Neves, E., Samões, R., Silva, A. M., & Santos, E. (2024). Characterization of Anti-GAD65-Associated Neurological Syndromes: Clinical Features and Antibody Titers. NeuroSci, 5(2), 201-208. https://doi.org/10.3390/neurosci5020015
Vancouver
Moura J, Sambayeta F, Sousa AP, Carneiro P, Neves E, Samões R, et al. Characterization of Anti-GAD65-Associated Neurological Syndromes: Clinical Features and Antibody Titers. NeuroSci. 2024;5(2):201-208. doi:10.3390/neurosci5020015
BibTeX
@article{Moura2024,
author = {Moura, João and Sambayeta, Firmina and Sousa, Ana Paula and Carneiro, Paula and Neves, Esmeralda and Samões, Raquel and Silva, Ana Martins and Santos, Ernestina},
title = {Characterization of Anti-GAD65-Associated Neurological Syndromes: Clinical Features and Antibody Titers},
journal = {NeuroSci},
year = {2024},
volume = {5},
number = {2},
pages = {201--208},
doi = {10.3390/neurosci5020015}
}
EUVIMED